|  |  |  |
| --- | --- | --- |
| **IRB-HSR# or UVA Study Tracking#** | | **PI:** |
| **Meeting Date:** | **Statistician Reviewer:** | |

|  |  |  |  |
| --- | --- | --- | --- |
| 1. **Does the study meet the criteria for IRB Approval per Federal Regulations?** ***(45CFR46.116/21CFR56.111)***   **INSTRUCTIONS**   * *If the question below is answered NO, the protocol cannot be approved.* * *See references in Appendix A to assist in addressing the criteria below.* * *These points must be discussed during the oral presentation at the IRB meeting.* * **FOR STATISTICAL REVIEW A RESPONSE TO APPROVAL CRITERIA #1 IS REQUIRED.** | | | |
| 1. Risks to participants are minimized by using procedures which are consistent with sound research design and do not unnecessarily expose participants to risk AND   whenever appropriate, that are already being performed for diagnostic or treatment procedures. | **YES** | **NO** |  |
| Points to Consider:   * Consider physical, psychological, social, legal and economic risks. * Can less risky procedures answer the question? * Can few procedures answer the question? Are the procedures needed at all? * Are the hypothesis and objectives clear? * Are there adequate preliminary data and is there appropriate justification for the research? * Are there qualified staff and resources to conduct the research? * Are all services/specialties involved in the research represented in the personnel? * Can different exclusion criteria reduce risk? * Is there a plan in place to manage any potential conflict of interest? * Are procedures that will answer the scientific question being performed for non- research purposes?   1. If so, can the data from these procedures be used to reduce the likelihood or magnitude of harm? * Is there a clear differentiation between research and usual practice? * Does the protocol present no more than minimal risk to subjects? If yes, continuations may be expedited | | | |
| *If NO, list conditions that must be met to meet this criterion:*   * + **Required Conditions** | | | |

***INSTRUCTIONS:***

1. *The IRB may require the following examples as conditions of approval of research:*

* *Confirmation of specific assumptions or understandings on the part of the IRB regarding how the research will be conducted (e.g., confirmation that the research excludes subjects who are cognitively impaired)*
* *Substantive changes to protocol or informed consent documents along with clearly stated parameters that the changes must satisfy (e.g. subject will be withdrawn if their hematocrit is less than ( insert level- but must be above 25%).*
* *Requiring revision to protocol to include the type and amount of standard contrast material to be used and designating a radiologist to review the protocol to ensure the use of the standard contrast material is medically appropriate.*
* *Rewriting the consent form into a lower lay language with review by the IRB chair to review the revisions to ensure the risks are accurately described*

1. *The IRB may NOT require the following examples as conditions of approval of research. These items would need to be included in a motion to Defer:*

* *Clarify your plan to provide additional subject monitoring*
* *Provide a justification for the use of a placebo or enrolling children in the study*
* *Revise the hypothesis or study design.*
* *Provide a description of the procedures the control group will undergo*
* *Clarify if subjects who have taken aspirin within 14 days prior to enrollment will be excluded from the study*
* *Approval from other UVa review committees such as HIRE, PRC etc. as their changes may affect the risk benefit analysis.*

**Appendix A: References Regarding Approval Criteria**

|  |
| --- |
| **1. Risks to subjects are minimized (i) by using procedures which are consistent with sound research design and do not unnecessarily expose subjects to risk, and (ii)whenever appropriate, by using procedures already being performed on the subjects for diagnostic or treatment purposes.**  Regulations and Guidance:   * DHHS: 45 CFR 46.111(a)(1), 45 CFR 46.111(a)(2), 45 CFR 46.111(a)(6) * FDA: 21 CFR 56.111(a)(1), 21 CFR 56.111(a)(2), 21CFR 56.111(a)(6); * Guidance for IRBs, Clinical Investigators, and Sponsors: IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed * DoD: Instruction 3216.02 6.b. * ICH-GCP: 2.2, 2.3, 3.13,4.2.1, 4.2.2, 4.2.3 * [AAHRPP Tip Sheet 1](https://admin.share.aahrpp.org/Website%20Documents/Tip_Sheet_1_Criteria_for_Approval_of_Research.PDF) * [AAHRPP Tip Sheet 20](https://admin.share.aahrpp.org/Website%20Documents/Tip_Sheet_20_Sufficient_Information_to_Determine_Whether_the_Criteria_for_Approval_are_Met.PDF) |

|  |
| --- |
| **2. Risks to subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the importance of the knowledge that may reasonably be expected to result.**  Regulations and Guidance:   * DHHS: 45 CFR 46.111(a)(1), 45 CFR 46.111(a)(2), 45 CFR 46.111(a)(6) * FDA: 21 CFR 56.111(a)(1), 21 CFR 56.111(a)(2), 21CFR 56.111(a)(6); * Guidance for IRBs, Clinical Investigators, and Sponsors: IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed * DoD: Instruction 3216.02 6.b. * ICH-GCP: 2.2, 2.3, 3.13,4.2.1, 4.2.2, 4.2.3 * [AAHRPP Tip Sheet 1](https://admin.share.aahrpp.org/Website%20Documents/Tip_Sheet_1_Criteria_for_Approval_of_Research.PDF) * [AAHRPP Tip Sheet 20](https://admin.share.aahrpp.org/Website%20Documents/Tip_Sheet_20_Sufficient_Information_to_Determine_Whether_the_Criteria_for_Approval_are_Met.PDF) |

|  |
| --- |
| **3. Selection of subjects’ is equitable, taking into account the purposes of the research, the setting in which the research will be conducted, the special problems of research involving vulnerable populations, the selection criteria and the recruitment process.**  Regulations and Guidance   * DHHS: 45 CFR 17.92, 45 CFR 46.111(a)(3), 45 CFR 46.116; OHRP Guidance on Written Institutional Review Board (IRB) Procedures * FDA: 21 CFR 56.111(a)(3), 21 CFR 50.20, 21 CFR 56.111(a)(3); FDA Information Sheets: Frequently Asked Questions: Informed Consent Document Content, Frequently Asked Questions: IRB Organization, A Guide to Informed Consent, Recruiting Study Subjects, Payment to Research Subjects * DoD: Instruction 3216.02 11; Dual Compensation Act, 24 U.S.C 301; DoD 3216.2, para. 4.4.4; SECNAVINST 3900.39D, para. 6a(6) * ICH-GCP: 3.1.8 * [AAHRPP Tip Sheet 1](https://admin.share.aahrpp.org/Website%20Documents/Tip_Sheet_1_Criteria_for_Approval_of_Research.PDF) * [AAHRPP Tip Sheet 20](https://admin.share.aahrpp.org/Website%20Documents/Tip_Sheet_20_Sufficient_Information_to_Determine_Whether_the_Criteria_for_Approval_are_Met.PDF)   If study regulated by DoD ( Department of Defense)  Verify the following additional protections are in place to minimize undue influence:   * + When research involves U.S. military personnel policies and procedures include additional protections for military research participants to minimize undue influence:     - Officers are not permitted to influence the decision of their subordinates.     - Officers and senior non-commissioned officers may not be present at the time of recruitment.     - Officers and senior non-commissioned officers have a separate opportunity to participate.     - When recruitment involves a percentage of a unit, an independent ombudsman is present.   + When research involves U.S. military personnel, policies and procedures require limitations on dual compensation:     - Prohibit an individual from receiving pay of compensation for research during duty hours.     - An individual may be compensated for research if the participant is involved in the research when not on duty.     - Federal employees while on duty and non- federal persons may be compensated for blood draws for research up to $50 for each blood draw.     - Non-federal persons may be compensated for research participating other than blood draws in a reasonable amount as approved by the IRB according to local prevailing rates and the nature of the research. |

|  |
| --- |
| **4. Informed consent will be sought from each prospective subject or the subject’s legally authorized representative.**  ***NA* Consent will not be obtained.**  Regulations and Guidance   * DHHS: 45 CFR 46.109(b), 45 CFR 46.109I, 45CFR 46.111(a)(4), 45 CFR 46.116, 45 CFR 46.117; * OHRP Guidance on Exculpatory Language in Informed Consent; * OHRP Guidance on Obtaining and Documenting Informed Consent of Subjects Who Do Not Speak English * FDA: 21 CFR 50.20, 21 CFR 56.109(b), 21 CFR 56.109(f), 21 CFR 56.111(a)(4), 21 CFR 50.25(a),21 CFR 50.25(b), 21 CFR 50.27(a), 21 CFR50.27(b), 21 CFR 56.111(a)(5); * FDA Information Sheets: A Guide to Informed Consent, Frequently Asked Questions: Informed Consent Document Content, Recruiting Study Subjects, IRB Procedures; FDA Information Sheets: Frequently Asked Questions: Informed Consent Process, Data Retention When Subjects Withdraw from FDA- Regulated Clinical Trials * DoD: Instruction 3216.2, para. 5.3.4; SECNAVINST 3900.39D, para. 6a(5) * ICH-GCP: 2.9, 3.1.5, 3.1.9, 4.3.4, 4.8.1-4.8.9, * 4.8.11 * [AAHRPP Tip Sheet 19.](https://admin.share.aahrpp.org/Website%20Documents/Tip_Sheet_19_State_and_Local_Law.PDF) * [AAHRPP Tip Sheet 20.](https://admin.share.aahrpp.org/Website%20Documents/Tip_Sheet_20_Sufficient_Information_to_Determine_Whether_the_Criteria_for_Approval_are_Met.PDF) |

|  |
| --- |
| **4a. The basic elements of the consent form per are included.**  **NA- A written consent form will not be obtained.**  Regulations and Guidance   * DHHS 45CFR46.116(a), .45CFR46.116(a)(5). * FDA...21CFR50.25(a), .21CFR50.25(a)(5)   Basic Elements  (1)Research: purpose, duration, procedures  (2)Risks/ Discomforts  (3)Benefits  (4)Alternatives  (5)Confidentiality  (6)Compensation for Injury  (7)Whom to contact  (8)Right to refuse, or withdraw without penalty |

|  |
| --- |
| **4b**. **The additional elements of the consent form are included when appropriate.**  **NA- A written consent form will not be obtained.**  Regulations and Guidance  DHHS45CFR46.116(b)  FDA 21CFR50.25(b)  Additional Elements   * + Unforeseeable Risks   + Termination Language   + Costs   + Consequences of withdrawing   + New Findings   + The approximate number of subjects involved in the study   + Compensation |

|  |
| --- |
| **4c. If consent / HIPAA authorization to be waived the following criteria are met**  **NA-Written consent and HIPAA Authorization will be obtained.**  Regulations and Guidance   * DHHS: 45 CFR 46.116I, 45 CFR 46.116(d),45CFR46.117I   + OHRP Guidance on Informed Consent-Legally Effective and Prospectively Obtained * FDA: 21 CFR 56.109I(1), 21 CFR 56.109(d) * HIPAA: 45CFR164.512(i)(2) * DoD: Instruction 3216.02 9. (2.1.1); 10 USC 980(a,b) * [AAHRPP Tip Sheet 1.](https://admin.share.aahrpp.org/Website%20Documents/Tip_Sheet_1_Criteria_for_Approval_of_Research.PDF) * [AAHRPP Tip Sheet 20.](https://admin.share.aahrpp.org/Website%20Documents/Tip_Sheet_20_Sufficient_Information_to_Determine_Whether_the_Criteria_for_Approval_are_Met.PDF)   Waiver of Consent/Parental Permission- DHHS Criteria:  *Must meet the criteria below if no consent to be obtained unless study is regulated by the Department of Defense.*  **DHHS: 45 CFR 46.116**  (d) An IRB may approve a consent procedure which does not include, or which alters, some or all of the elements of informed consent set forth in this section, or waive the requirements to obtain informed consent provided the IRB finds and documents that:   1. The research involves no more than minimal risk to the subjects; 2. The waiver or alterations will not adversely affect the rights and welfare of the subjects; 3. The research could not practicably be carried out without the waiver or alteration; and 4. Whenever appropriate, the subjects will be provided with additional pertinent information after participation.   Waiver of Consent/Parental Permission- Department of Defense Criteria:  *Must meet the criteria below if no consent to be obtained and study is regulated by the Department of Defense.*  **DoD: Instruction 3216.02 9. (2.1.1); 10 USC 980(a,b)**  (d) An IRB may approve a consent procedure which does not include, or which alters, some or all of the  elements of informed consent set forth in this section, or waive the requirements to obtain informed  consent provided the IRB finds and documents that:  (1) The research involves no more than minimal risk to the subjects;  (2) The waiver or alteration will not adversely affect the rights and welfare of the subjects;  (3) The research could not practicably be carried out without the waiver or alteration; and  (4) Whenever appropriate, the subjects will be provided with additional pertinent information after participation.  Waiver of HIPAA Authorization Criteria:  *Must meet the criteria below if no HIPAA Authorization to be obtained and study involves collection of identifiable health information.*  **HIPAA 45CFR164.512(i)(2)**  (ii) Waiver criteria A statement that the IRB or privacy board has determined that the alteration or waiver, in whole or in part, of authorization satisfies the following criteria:   1. The use or disclosure of protected health information involves no more than minimal risk to the privacy of individuals, based in, at least, the presence of the following elements; 2. An adequate plan to protect the identifiers from improper use and disclosure; 3. An adequate plan to destroy the identifiers at the earliest opportunity consistent with conduct of the research, unless there is a health or research justification for retaining the identifiers or such retention is otherwise required by law; and 4. Adequate written assurances that the protected health information will not be reused or disclosed to any other person or entity, except as required by law, for authorized oversight of the research study, or for other research for which the use or disclosure of protected health information would be permitted by this subpart. 5. The research could not practicably be conducted without the waiver or alteration and 6. The research could not practicably be conducted without access to and use of the protected health information.   Points to Consider:  • Will the participant or the participant’s legally authorized representative sign and date the consent document?  • Will a copy of the consent document be given to the person signing the consent document?  Waiver of Consent/Parental Permission: FDA Criteria  *Must meet the criteria below if no consent to be obtained on an individual subject basis and study is regulated by the FDA (requires and IND or IDE).*  **21CFR50.23 (FDA)**   * + - 1. The obtaining of informed consent shall be deemed feasible unless, before use of the test article (except as provided in paragraph (b) of this section), both the investigator and a physician who is not otherwise participating in the clinical investigation certify in writing all of the following:  1. The human subject is confronted by a life-threatening situation necessitating the use of the test article. 2. Informed consent cannot be obtained from the subject because of an inability to communicate with, or obtain legally effective consent from the subject. 3. Time is not sufficient to obtain consent from the subject’s legal representative. 4. There is available no alternative method of approved or generally recognized therapy that provides an equal or greater likelihood of saving the life of the subject. 5. If immediate use of the test article is, in the investigator’s opinion, required to preserve the life of the subject, and time is not sufficient to obtain the independent determination required in paragraph (a) of this section in advance of using the test article, the determinations of the clinical investigator shall be made and within 5 working days after the use of the article, be reviewed and evaluated in writing by a physician who is not participating in the clinical investigation. 6. The documentation required in paragraph (a) or (b) of this section shall be submitted to the IRB within 5 working days after the use of the test article.   **OR**  *Must meet the criteria below if the study is regulated by the FDA (requires and IND or IDE) and if more than 1 subject will need to be enrolled with no consent. (e.g. EFIC study)*  **21CFR50.24 (FDA)**  (a) The IRB responsible for the review, approval, and continuing approve that investigation without requiring that informed consent of all research subjects be obtained if the IRB (with the concurrence of a licensed physician who is a member of or consultant to the IRB and who is not otherwise participating in the clinical investigation) finds and documents each of the following:  (1) The human subjects are in a life-threatening situation, available treatments are unproven or unsatisfactory, and the collection of valid scientific evidence, which may include evidence obtained through randomized placebo-controlled investigations, is necessary to determine the safety and effectiveness of particular interventions.  (2) Obtaining informed consent is not feasible because:  (i) The subjects will not be able to give their informed consent as a result of their medical condition;  (ii) The intervention under investigation must be administered before consent from the subjects’ legally authorized representatives is feasible; and  (iii) There is no reasonable way to identify prospectively the individuals likely to become eligible for participation in the clinical investigation.  (3) Participation in the research holds out the prospect of direct benefit to the subjects because:  (i) Subjects are facing a life-threatening situation that necessitates intervention;  (ii) Appropriate animal and other pre clinical studies have been conducted, and the information derived from those studies and related evidence support the potential for the intervention to provide a direct benefit to the individual subjects; and  (iii) Risks associated with the investigation are reasonable in relation to what is known about the medical condition of the potential class of subjects, the risks and benefits of standard therapy, if any, and what is known about the risks and benefits of the proposed intervention or activity.  (4) The clinical investigation could not practicably be carried out without the waiver.  (5) The proposed investigational plan defines the length of the potential therapeutic window based on scientific evidence, and the investigator has committed to attempting to contact a legally authorized representative for each subject within that window of time and, if feasible, to asking the legally authorized representative contacted for consent within that window rather than proceeding without consent. The investigator will summarize efforts made to contact legally authorized representatives and make this information available to the IRB at the time of continuing review.  (6) The IRB has reviewed and approved informed consent procedures and an informed consent document consistent with Sec. 50.25. These procedures and the informed consent document are to be used with subjects or their legally authorized representatives in situations where use of such procedures and documents is feasible. The IRB has reviewed and approved procedures and information to be used when providing an opportunity for a family member to object to a subject’s participation in the clinical investigation consistent with paragraph (a)(7)(v) of this section.  (7) Additional protections of the rights and welfare of the subjects will be provided, including, at least:  (i) Consultation (including, where appropriate, consultation carried out by the IRB) with representatives of the communities in which the clinical investigation will be conducted and from which the subjects will be drawn;  (ii) Public disclosure to the communities in which the clinical investigation will be conducted and from which the subjects will be drawn, prior to initiation of the clinical investigation, of plans for the investigation and its risks and expected benefits;  (iii) Public disclosure of sufficient information following completion of the clinical investigation to apprise the community and researchers of the study, including the demographic characteristics of the research population, and its results;  (iv) Establishment of an independent data monitoring committee to exercise oversight of the clinical investigation; and  (v) If obtaining informed consent is not feasible and a legally authorized representative is not reasonably available, the investigator has committed, if feasible, to attempting to contact within the therapeutic window the subject’s family member who is not a legally authorized representative, and asking whether he or she objects to the subject’s participation in the clinical investigation. The investigator will summarize efforts made to contact family members and make this information available to the IRB at the time of continuing review.  (b) The IRB is responsible for ensuring that procedures are in place to inform, at the earliest feasible opportunity, each subject, or if the subject remains incapacitated, a legally authorized representative of the subject, or if such a representative is not reasonably available, a family member, of the subject’s inclusion in the clinical investigation, the details of the investigation and other information contained in the informed consent document. The IRB shall also ensure that there is a procedure to inform the subject, or if the subject remains incapacitated, a legally authorized representative of the subject, or if such a representative is not reasonably available, a family member, that he or she may discontinue the subject’s participation at any time without penalty or loss of benefits to which the subject is otherwise entitled. If a legally authorized representative or family member is told about the clinical investigation and the subject’s condition improves, the subject is also to be informed as soon as feasible. If a subject is entered into a clinical investigation with waived consent and the subject dies before a legally authorized representative or family member can be contacted, information about the clinical investigation is to be provided to the subject’s legally authorized representative or family member, if feasible.  I The IRB determinations required by paragraph (a) of this section and the documentation required by paragraph I of this section are to be retained by the IRB for at least 3 years after completion of the clinical investigation, and the records shall be accessible for inspection and copying by FDA in accordance with Sec. 56.115(b) of this chapter.  (d) Protocols involving an exception to the informed consent requirement under this section must be performed under a separate investigational new drug application (IND) or investigational device exemption (IDE) that clearly identifies such protocols as protocols that may include subjects who are unable to consent. The submission of those protocols in a separate IND/IDE is required even if an IND for the same drug product or an IDE for the same device already exists. Applications for investigations under this section may not be submitted as amendments under Secs. 312.30 or 812.35 of this chapter.  If an IRB determines that it cannot approve a clinical investigation because the investigation does not meet the criteria in the exception provided under paragraph (a) of this section or because of other relevant ethical concerns, the IRB must document its findings and provide these findings promptly in writing to the clinical investigator and to the sponsor of the clinical investigation. The sponsor of the clinical investigation must promptly disclose this information to FDA and to the sponsor’s clinical investigators who are participating or are asked to participate in this or a substantially equivalent clinical investigation of the sponsor, and to other IRBs that have been, or are, asked to review this or a substantially equivalent investigation by that sponsor. |

|  |
| --- |
| **4d. Waiver of Documentation of Consent** (e.g. verbal consent )  **NA-Written consent will be obtained.**  **FDA Regulations:**  *The criteria below must be met if requesting “verbal consent” and study is regulated by the FDA (has an IND/IDE).*  The IRB may, for some or all subjects, waive the requirement that the subject, or the subject’s legally authorized representative, sign a written consent form if it finds:   * That the research presents no more than minimal risk of harm to subjects and involves no procedures for which written consent is normally required outside the research context   **OR**   * Find that the requirements in 21CFR50.24 for an exception from informed consent for emergency research are met.   **DoD Regulations*:***  *The criteria below must be met if requesting “verbal consent”,*  **32CFR219.117I**  An IRB may waive the requirement for the investigator to obtain a signed consent form for some or  all subjects if it finds either:  (1)That the only record linking the subject and the research would be the consent document and the  principal risk would be potential harm resulting from a breach of confidentiality. Each subject will be  asked whether the subject wants documentation linking the subject with the research, and the subject’s  wishes will govern; or  **OR**  (2) That the research presents no more than minimal risk of harm to subjects and involves no procedures  for which written consent is normally required outside of the research context. In cases in which the  documentation requirement is waived, the IRB may require the investigator to provide subjects with a  written statement regarding the research.  **HIPAA 45CFR164.512(i)(2)**  (ii) Waiver criteria A statement that the IRB or privacy board has determined that the alteration or waiver, in whole or in part, of authorization satisfies the following criteria:   1. The use or disclosure of protected health information involves no more than minimal risk to the privacy of individuals, based in, at least, the presence of the following elements; 2. An adequate plan to protect the identifiers from improper use and disclosure; 3. An adequate plan to destroy the identifiers at the earliest opportunity consistent with conduct of the research, unless there is a health or research justification for retaining the identifiers or such retention is otherwise required by law; and 4. Adequate written assurances that the protected health information will not be reused or disclosed to any other person or entity, except as required by law, for authorized oversight of the research study, or for other research for which the use or disclosure of protected health information would be permitted by this subpart. 5. The research could not practicably be conducted without the waiver or alteration and 6. The research could not practicably be conducted without access to and use of the protected health information. |

|  |
| --- |
| 5.**Informed consent will be appropriately documented in accordance with and to the extent required.**  **NA-Consent will not be obtained.**  Regulations and Guidance   * DHHS: 45 CFR 46.109(b), 45 CFR 46.109(e), 45CFR 46.111(a)(4), 45 CFR 46.116, 45 CFR 46.117; * OHRP Guidance on Exculpatory Language in Informed Consent; * OHRP Guidance on Obtaining and Documenting Informed Consent of Subjects Who Do Not Speak English * FDA: 21 CFR 50.20, 21 CFR 56.109(b), 21 CFR 56.109(f), 21 CFR 56.111(a)(4), 21 CFR 50.25(a),21 CFR 50.25(b), 21 CFR 50.27(a), 21 CFR50.27(b), 21 CFR 56.111(a)(5); * FDA Information Sheets: A Guide to Informed Consent, Frequently Asked Questions: Informed Consent Document Content, Recruiting Study Subjects, IRB Procedures; FDA Information Sheets: Frequently Asked Questions: Informed Consent Process, Data Retention When Subjects Withdraw from FDA- Regulated Clinical Trials * DoD: Instruction 3216.2, para. 5.3.4; SECNAVINST 3900.39D, para. 6a(5) * ICH-GCP: 2.9, 3.1.5, 3.1.9, 4.3.4, 4.8.1-4.8.9, * 4.8.11 * [AAHRPP Tip Sheet 19.](https://admin.share.aahrpp.org/Website%20Documents/Tip_Sheet_19_State_and_Local_Law.PDF) * [AAHRPP Tip Sheet 20.](https://admin.share.aahrpp.org/Website%20Documents/Tip_Sheet_20_Sufficient_Information_to_Determine_Whether_the_Criteria_for_Approval_are_Met.PDF) |

|  |
| --- |
| **6. When appropriate, the research plan makes adequate provision for monitoring the data collected to ensure the safety of subjects.**  Regulations and Guidance   * DHHS: 45 CFR 46.111(a)(6) * FDA: 21 CFR 56.111(a)(6) * DoD: Instruction 3216.02 8; SECNAVINST 3900.39D, para. 6c * ICH-GCP: 5.1.6 * [AAHRPP Tip Sheet 1](https://admin.share.aahrpp.org/Website%20Documents/Tip_Sheet_1_Criteria_for_Approval_of_Research.PDF) * AAHRPP Tip Sheet 6. * [AAHRPP Tip Sheet 20](https://admin.share.aahrpp.org/Website%20Documents/Tip_Sheet_20_Sufficient_Information_to_Determine_Whether_the_Criteria_for_Approval_are_Met.PDF) |

|  |
| --- |
| **7a.When appropriate, there are adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data.**  Regulations and Guidance   * DHHS: 45 CFR 46.111(a)(7) * FDA: 21 CFR 56.111(a)(7) * ICH-GCP: 2.11 * AAHRPP Tip Sheet 1. * [AAHRPP Tip Sheet 4.](https://admin.share.aahrpp.org/Website%20Documents/Tip_Sheet_4_Evaluating_the_Maintenance_of_Confidentiality_of_Data_in_Proposed_Research.PDF) * AAHRPP Tip Sheet 5. * AAHRPP Tip Sheet 20. |

|  |
| --- |
| **7b.** When some or all of the subjects are likely to be vulnerable to coercion or undue influence, such as **children, prisoners, pregnant women, mentally disabled persons, or economically or educationally disadvantaged persons, students, employees, paroles, terminally ill etc.** additional safeguards continue to be included in the study to protect the rights and welfare of these subjects.   * DHHS: 45 CFR 46.111(b), 45 CFR 46 Subpart B, 45 CFR 46 Subpart C, 45 CFR 46 Subpart D, 45 CFR 46.111(b), 45 CFR 46.205; OHRP Guidance on Special Protections for Children as Research Subjects, * OHRP Guidance on the Involvement of Prisoners in Research, May 23, 2003; 45 CFR 46 Waiver of the Applicability of Certain Provisions of Department of Health and Human Services Regulations for Protection of Human Research Subjects for Department of Health and Human Services Conducted or Supported Epidemiologic Research Involving Prisoners as Subjects (Federal Register, Vol. 68, No. 119, pp. 36929-36931, Friday, June 20, 2003) * FDA: 21 CFR 50.3, 21 CFR 50 Subpart D, 21 CFR 56.111(b), 21 CFR 56.111(c) * VA: 38 CFR 16.111(b); VHA Directive 2001-028; VHA Handbook 1200.05, 36, 45, 46, 47, 48, 49 * DoD: Instruction 3216.02 7; SECNAVINST 3900.39D, para. 6a(8); 10 U.S.C. 980 * ICH-GCP: 4.8.13, 4.8.14 * AAHRPP Tip Sheet 1. * AAHRPP Tip Sheet 11. * AAHRPP Tip Sheet 18. * AAHRPP Tip Sheet 20. * AAHRPP Tip Sheet 26. |